OpenURL Connection Search

Select item for more details and to access through your institution.

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Published in:
Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34839-9
By:
- Donovan-Banfield, I'ah;
- Penrice-Randal, Rebekah;
- Goldswain, Hannah;
- Rzeszutek, Aleksandra M.;
- Pilgrim, Jack;
- Bullock, Katie;
- Saunders, Geoffrey;
- Northey, Josh;
- Dong, Xiaofeng;
- Ryan, Yan;
- Reynolds, Helen;
- Tetlow, Michelle;
- Walker, Lauren E.;
- FitzGerald, Richard;
- Hale, Colin;
- Lyon, Rebecca;
- Woods, Christie;
- Ahmad, Shazaad;
- Hadjiyiannakis, Dennis;
- Periselneris, Jimstan
Publication type:
Article
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways.
Published in:
Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-33096-0
By:
- Quinn, Leonard M.;
- Haldenby, Sam;
- Antzcak, Philip;
- Fowler, Anna;
- Bullock, Katie;
- Kenny, John;
- Gilbert, Timothy;
- Andrews, Timothy;
- Diaz-Nieto, Rafael;
- Fenwick, Stephen;
- Jones, Robert;
- Costello-Goldring, Eithne;
- Poston, Graeme;
- Greenhalf, William;
- Palmer, Daniel;
- Malik, Hassan;
- Goldring, Chris
Publication type:
Article
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Published in:
Clinical Infectious Diseases, 2022, v. 75, n. 1, p. e525, doi. 10.1093/cid/ciac199
By:
- FitzGerald, Richard;
- Dickinson, Laura;
- Else, Laura;
- Fletcher, Thomas;
- Hale, Colin;
- Amara, Alieu;
- Walker, Lauren;
- Penchala, Sujan Dilly;
- Lyon, Rebecca;
- Shaw, Victoria;
- Greenhalf, William;
- Bullock, Katie;
- Lavelle-Langham, Lara;
- Reynolds, Helen;
- Painter, Wendy;
- Holman, Wayne;
- Ewings, Sean;
- Griffiths, Gareth;
- Khoo, Saye
Publication type:
Article
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Published in:
2021
By:
- Khoo, Saye H;
- Fitzgerald, Richard;
- Fletcher, Thomas;
- Ewings, Sean;
- Jaki, Thomas;
- Lyon, Rebecca;
- Downs, Nichola;
- Walker, Lauren;
- Tansley-Hancock, Olana;
- Greenhalf, William;
- Woods, Christie;
- Reynolds, Helen;
- Marwood, Ellice;
- Mozgunov, Pavel;
- Adams, Emily;
- Bullock, Katie;
- Holman, Wayne;
- Bula, Marcin D;
- Gibney, Jennifer L;
- Saunders, Geoffrey
Publication type:
journal article

Found: 4

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways.

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.